IgA Response to ESAT-6/CFP-10 and Rv2031 Antigens Varies in Patients With Culture-Confirmed Pulmonary Tuberculosis, Healthy Mycobacterium tuberculosis-Infected and Non-Infected Individuals in a Tuberculosis Endemic Setting, Ethiopia

Scandinavian Journal of Immunology

Volumn 78, Issue 3, 2013, Pages 266-274

  Legesse, M ^a,b   Ameni, G ^a   Medhin, G ^a   Mamo, G ^a,b   Franken, K L M C ^c   Ottenhoff, T H M ^c   Bjune, G ^b   Abebe, F ^b  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b UNIVERSITY OF OSLO   (Norway)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RV2031 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHIOPIA; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; OPTICAL DENSITY; PRIORITY JOURNAL; VENOUS BLOOD;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; COHORT STUDIES; ETHIOPIA; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84883002189     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12080     Document Type: Article

References (55)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;287:677-86.
2. Young LS. Mycobacterial diseases and the compromised host. Clin Infect Dis 1993;17(Suppl. 2):S436-41.
3. Dannenberg AM Jr. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology 1994;191:461-73.
4. Wiker HG, Mustafa T, Bjune GA, Harboe M. Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect Dis 2010;10:37.
5. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of latent tuberculosis infection in patients living with HIV infection. Clin Dev Immunol 2011; 2011. doi: 10.1155/2011/980594.
6. Falla JC, Parra CA, Mendoza M et al. Identification of B-and T-cell epitopes within the MTP40 protein of Mycobacterium tuberculosis and their correlation with the disease course. Infect Immun 1991;59:2265-73.
7. Mattos AMM, Almeida CDS, Franken KLMC et al. Increased IgG1, IFN-g, TNF-a and IL-6 responses to Mycobacterium tuberculosis antigens in patients with Tuberculosis are lower after chemotherapy. Int Immunol 2010; 22: 775-782.
8. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998;11:514-32.
9. Glatman-Freedman A. The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy. Tuberculosis 2006;86:191-7.
10. Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol 2009;157:235-43.
11. Costello AML, Kumar A, Narayan V et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans R Soc Trop Med Hyg 1992;86:686-97.
12. Arias-Bouda LMP, Kuijper S, Van Der Werf A, Nguyen LN, Jansen HM, Kolk AHJ. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in Sera of patients undergoing treatment for pulmonary tuberculosis. Clin Diagn Lab Immunol 2003; 10: 702-709.
13. Demkow U, Filewska M, Michalowska-Mitczuk D et al. Heterogeneity of antibody response to myobacterial antigens in different clinical manifestations of pulmonary tuberculosis. J Physiol Pharmacol 2007;58:117-27.
14. Hoff ST, Abebe M, Ravn P et al. Evaluation of Mycobacterium tuberculosis-specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and Denmark. Clin Infect Dis 2007;45:575-82.
15. Reljic R, Williams A, Ivanyi J. Mucosal immunotherapy of tuberculosis: is there a value in passive IgA. Tuberculosis 2006;86:176-90.
16. Kerr MA. The structure and function of human IgA. Biochem J 1990;271:285-96.
17. Monteiro RC, van de Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177-204.
18. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998;144:3195-203.
19. Brosch R, Gordon SV, Marmiesse M et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002;99:3684-9.
20. Guinn KM, Hickey MJ, Mathur SK et al. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004;51:359-70.
21. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104.
22. Yuan Y, Crane DD, Barry CE 3rd. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 1996;178:4484-92.
23. Hu Y, Movahedzadeh F, Stoker NG, Coates ARM. Deletion of the Mycobacterium tuberculosis α-crystallin-like hspXGene causes increased bacterial growth in vivo. Infect Immun 2006;74:861-8.
24. Ottenhoff THM, Kaufmann SHE. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012;8:e1002607.
25. Taylor JL, Wieczorek A, Keyser AR et al. HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule. Immunol Cell Biol 2012;10:945-54.
26. Senol G, Ecevit C, Oztürk A. Humoral immune response against 38- and 16-kDa mycobacterial antigens in childhood tuberculosis. Pediatr Pulmonol 2009;44:839-44.
27. Demissie A, Leyten EM, Abebe M et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006;13:179-86.
28. Leyten EM, Lin MY, Franken KL et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006;8:2052-60.
29. Davidow A, Kanaujia GV, Shi L et al. Antibody profiles characteristic of Mycobacterium tuberculosis infection state. Infect Immun 2005;73:6846-51.
30. Raja A, Uma Devi KR, Ramalingam B, Brennan PJ. Immunoglobulin G, A, and M responses in serum and circulating immune complexes elicited by the 16-kilodalton antigen of Mycobacterium tuberculosis. Clin Diagn Lab Immunol 2002;9:308-12.
31. Legesse M, Ameni G, Mamo G, Medhin G, Bjune G, Abebe F. Community-based cross-sectional survey of latent tuberculosis infection in Afar pastoralists, Ethiopia, using QuantiFERON-TB Gold In-Tube and tuberculin skin test. BMC Infect Dis 2011;11:89.
32. WHO. Global Tuberculosis Control. Geneva: Switzerland, 2009. ISBN: 9789241563802.
33. Legesse M, Ameni G, Mamo G et al. Knowledge and perception of pulmonary tuberculosis in pastoral communities in the middle and Lower Awash Valley of Afar region, Ethiopia. BMC Public Health 2010;10:187.
34. Legesse M, Ameni G, Mamo G, Medhin G, Bjune G, Abebe F. Performance of QuantiFERON-TB Gold In-Tube (QFTGIT) for the diagnosis of Mycobacterium tuberculosis (Mtb) infection in Afar Pastoralists, Ethiopia. BMC Infect Dis 2010;10:354.
35. Dhingra VK, Aggarwal N, Rajpal S, Aggarwal JK, Gaur SN. Validity and reliability of sputum smear examination as diagnostic and screening test for tuberculosis. Indian J Allergy Asthma Immunol 2003;17:67-9.
36. Kaushik A, Singh UB, Porwal C et al. Diagnostic potential of 16 kDa (HspX, α-crystalline) antigen for serodiagnosis of tuberculosis. Indian J Med Res 2012;135:771-7.
37. Limongi LC, Olival L, Conde MB, Junqueira-Kipnis AP. Determination of levels of specific IgA to the HspX recombinant antigen of Mycobacterium tuberculosis for the diagnosis of pleural tuberculosis. J Bras Pneumol 2011;37:302-7.
38. Conde MB, Suffys P, Lapa E Silva JR, Kritski AL, Dorman S. Immunoglobulin A(IgA) and IgG immune responses against P-90 antigen for the diagnosis of pulmonary tuberculosis and screening for Mycobacterium tuberculosis infection. Clin Diagn Lab Immunol 2004;11:94-7.
39. Arikan S, Tuncer S, Us D, Unal S, Ustaçelebi S. Anti-Kp 90 IgA antibodies in the diagnosis of active tuberculosis. Chest 1998;114:1253-7.
40. Bezerra MJ, Beck ST, Kanunfre KA, Leite OM, Ferreira AW. A study of IgA antibody response to different Mycobacterium tuberculosis antigens in the diagnosis and monitoring of pulmonary tuberculosis. Braz J Infect Dis 2009;13:53-8.
41. Skvor J, Trnka L, Kugukovova L. Immunoprofile studies in patients with pulmonary tuberculosis. II-Correlation of levels of different classes of immunoglobulins and specific antibodies with the extent of tuberculosis. Scand J Respir Dis 1979; 60: 168-71.
42. Rohini K, Srikumar PS, Mahesh Kumar AA. Study on the serum immunoglobulin levels in pulmonary tuberculosis patients. Int J Biosci Biochem Bioinforma 2012;2:280-1.
43. Warke SS, Khan ZH. Effect of antituberculosis drugs on serum immunoglobulins of pulmonary tuberculosis patients. Biosci Biotech Res Comm 2011;4:168-72.
44. Alifano M, De Pascalis R, Sofia M, Faraone S, Del Pezzo M, Covelli I. Evaluation of IgA-mediated humoral immune response against the mycobacterial antigen P-90 in diagnosis of pulmonary tuberculosis. Chest 1997;111:601-5.
45. Julia′n E, Matas L, Pe′rez A, Alcaide J, Lane′elle M, Luquin M. Serodiagnosis of tuberculosis: comparison of immunoglobulin A (IgA) response to sulfolipid I with IgG and IgM responses to 2, 3-diacyltrehalose, 2, 3, 6-triacyltrehalose, and cord factor antigens. J Clin Microbiol 2002; 40: 3782-8.
46. Khosravi AD, Torabizadeh R, Landi A. Investigation of the level of IgG, IgM and IgA antibodies against A60 antigen in tuberculosis patients referred to Phls, Ahvaz, Iran. Pak J Med Sci 2005;21:465-9.
47. Fujita Y, Doi T, Sato K, Yano I. Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis. Microbiology 2005; 151: 2065-74.
48. Silva VM, Kanaujia G, Gennaro ML, Menzies D. Factors associated with humoral response to ESAT-6, 38 kDa and 14 kDa in patients with a spectrum of tuberculosis. Int J Tuberc Lung Dis 2003;7:478-84.
49. Bothamley GH, Rudd R, Festenstein F, Ivanyi J. Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis. Thorax 1992;47:270-5.
50. Hussain R, Dawood G, Abrar N et al. Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients. Clin Diagn Lab Immunol 1995;2:726-32.
51. Kunnath-Velayudhan S, Gennaro ML. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. Clin Microbiol Rev 2011;24:792-805.
52. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013;13:250-62.
53. Falero-Diaz G, Challacombe S, Banerjee D, Douce G, Boyd A, Ivanyi J. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 2000;18:3223-9.
54. Williams A, Reljic R, Naylor I et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004;111:328-33.
55. Rodr′idotlessguez A, Tj̈arnlund A, Ivanji J et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 2005;23:2565-72.